The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Weekly paclitaxel and bevacizumab as fourth-line treatment or beyond for metastatic nonsquamous non-small cell lung cancer.
Stefanie Habib
No relevant relationships to disclose
Julie Delourme
Research Funding - Roche
Xavier Dhalluin
Research Funding - Roche
Arnaud Scherpereel
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Jean-Jacques Lafitte
Research Funding - Roche
Alexis B. Cortot
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche